Ivermectin Exeltis (Ivermectin)

Ivermectin acts by binding to glutamate‑gated chloride channels that are unique to many invertebrate parasites. This binding opens the channels, allowing an influx of chloride ions, which hyperpolarizes the parasite’s nerve or muscle cells. The resulting paralysis prevents the parasite from feeding or moving, leading to its death while sparing human cells that lack these specific channels.

The exact dose of Ivermectin Exeltis is determined by the prescribing clinician based on the specific indication, the patient’s body weight, age, and overall health status. Dosage regimens differ for onchocerciasis, strongyloidiasis, cutaneous larva migrans, and scabies, and the prescriber will follow approved guidelines or local practice standards.

Safety data for Ivermectin Exeltis in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative treatments or risk‑benefit considerations with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Ivermectin Exeltis. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Ivermectin Exeltis offers a broad spectrum of activity against several nematodes and ectoparasites, often requiring a single dose for conditions like onchocerciasis and scabies. Compared with albendazole or mebendazole, ivermectin may be more effective for certain skin‑related migrations and for microfilarial infections, though combination therapy is sometimes used to enhance efficacy or prevent resistance.

Ivermectin Exeltis should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging to protect it from moisture, light, and humidity. Do not store in areas with excessive heat or direct sunlight, and keep it out of reach of children.

Ivermectin Exeltis is taken orally, usually with a full glass of water. Depending on the indication, it may be taken with or without food; the prescribing information will specify any particular requirements. The tablet (or other oral form) should be swallowed whole and not chewed or crushed unless directed by a healthcare professional.

While most patients tolerate Ivermectin Exeltis well, serious adverse events can include severe skin reactions such as Stevens‑Johnson syndrome, liver injury manifested by elevated enzymes or hepatitis, and neurologic effects like seizures or altered consciousness. Any signs of these reactions require immediate medical attention and discontinuation of the drug.

Ivermectin Exeltis should be avoided in individuals with known hypersensitivity to ivermectin or any of the product’s excipients. Patients with severe hepatic impairment should not use it without specialist advice. It is also contraindicated in children weighing less than 15 kg for certain indications, and caution is advised in pregnant or nursing women when safer alternatives exist.